Salesforce Stock Is at a 3-Year Low. Should Investors Consider Buying?

Salesforce shares are down more than 40% in 2026 and closed slightly above $153 on June 23, despite last quarter revenue and earnings beating expectations and generating $6.6 billion of free cash flow. The article highlights two main concerns: AI cannibalization risk from Agentforce and Salesforce's $3.6 billion acquisition of Fin, which adds about 30,000 business customers but raises questions about growth-by-acquisition. Overall, the piece is cautiously constructive on fundamentals but framed by weak sentiment and valuation pressure.

Analysis

CRM’s setup is less about a broken business and more about a market repricing of durability. The key issue is that AI monetization may shift value from per-seat expansion to usage-based workflows, which can compress ARR visibility before it improves total customer spend; that transition usually creates a two-step equity path: multiple compression first, then a rerate only after AI contribution is legible in bookings. In that window, the stock can look cheap for months while fundamentals remain fine.

The acquisition angle matters because it signals that CRM is prioritizing distribution capture over organic product-led share gains. That can be smart if it lowers customer acquisition cost and accelerates cross-sell, but it also raises the probability that future growth is being subsidized with capital rather than earned through net-new product demand. The second-order effect is that competitors with cleaner AI narratives and less integration risk can win incremental mindshare even if their absolute product breadth is weaker.

The market is likely overstating near-term cannibalization and understating medium-term operating leverage. If AI agents reduce low-value seat growth but increase platform penetration, the eventual winner is the vendor that can package AI into higher-margin workflows and price by outcome rather than seat count. The risk is that this transition takes 2-4 quarters longer than bulls expect, keeping the stock range-bound despite healthy cash generation.

Consensus is missing that this is primarily a sentiment/positioning trade until the company proves AI is additive at scale. That makes the asymmetry attractive for patient capital, but not for a straight-line long: the stock can rally hard on one strong enterprise AI monetization update, yet still underperform if the next few quarters show the same high-quality but unexciting growth profile.

Key Decisions for Investors

• Buy CRM on 3-6 month weakness only, sizing for a mean-reversion trade rather than a secular re-rating; upside is strongest if management can show AI attach rates improving while FCF stays >$6B/qtr, but thesis breaks if growth decelerates another leg lower.
• Use a call spread in CRM 6-12 months out instead of stock to express upside from an AI monetization inflection; reward is convex if sentiment turns, while premium paid limits downside if cannibalization fears persist.
• Pair long CRM / short a higher-multiple software peer with less cash flow support over a 1-2 quarter horizon; the relative trade favors CRM if investors rotate back toward profitable AI platforms, but exit if CRM loses margin discipline.
• Avoid chasing the stock on acquisition headlines; wait for post-deal integration commentary and first two quarters of customer retention data, since the market may initially reward the deal but punish any sign of slower organic bookings.
• For existing holders, consider selling cash-secured puts below current levels to get paid while waiting for better entry; this works best if the market continues to overdiscount AI cannibalization without evidence of margin deterioration.